TOKYO, Jun 02 (Pulse News Wire) – RaQualia Pharma Inc. (4579.T) announced today its collaboration with the Research Institute for Electronic Science (RIKEN) to develop drug discovery support technology that integrates computational chemistry and experimental data.
The joint research aims to enhance the efficiency and sophistication of drug development processes through the optimization of virtual screening methods, rational compound design based on binding free energy, and advanced compound generation using AI-driven structural creation. The project, led by Dr.
Mitsugu Hongo from RIKEN's Life Science and Medical Sciences Research Center, will leverage the expertise and technologies of both institutions to validate computational results against experimental data continuously. RaQualia Pharma expects this collaboration to strengthen its research capabilities and contribute to the long-term enhancement of its development portfolio and pipeline expansion.
Regarding the impact on fiscal year 2026 (January 01, 2026 to December 31, 2026) earnings forecast, the company stated that the effects would be minor and that there would be no changes to the previously disclosed outlook released on February 13, 2026.
🟢 Confidence: High AI-translated content.